European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

(2013) J. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

(2013) A. Hochhaus et al.   BLOOD

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

(2013) P. Neelakantan et al.   BLOOD

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure

(2013) Elias Jabbour et al.   Clinical Lymphoma Myeloma & Leukemia

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

(2013) T D Kim et al.   LEUKEMIA

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

(2013) F J Giles et al.   LEUKEMIA

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

(2012) E. Warlick et al.   BLOOD

The shady side of dasatinib

(2012) A. Zarbock   BLOOD

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

(2012) S. Luatti et al.   BLOOD

How I treat CML blast crisis

(2012) R. Hehlmann   BLOOD

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

(2012) J. Cortes et al.   BLOOD

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

(2012) J. Guilhot et al.   BLOOD

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

(2012) H. J. Khoury et al.   BLOOD

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

(2012) D. Marin et al.   BLOOD

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

(2012) J. S. Khorashad et al.   BLOOD

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

(2012) H. Kantarjian et al.   BLOOD

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

(2012) J. P. Radich et al.   BLOOD

Dasatinib inhibits proinflammatory functions of mature human neutrophils

(2012) K. Futosi et al.   BLOOD

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

(2012) F Efficace et al.   BRITISH JOURNAL OF CANCER

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2012) Xuelin Huang et al.   CANCER

Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia

(2012) Poe-Hirr Hsyu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

(2012) R. Gurion et al.   HAEMATOLOGICA

Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty

(2012) F. Giona et al.   HAEMATOLOGICA

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

(2012) S. Angelini et al.   HAEMATOLOGICA

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

(2012) N. Pemmaraju et al.   HAEMATOLOGICA

Clinical cardiac safety profile of nilotinib

(2012) T. D. Kim et al.   HAEMATOLOGICA

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation

(2012) Dongho Kim et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib

(2012) Susan Branford et al.   JOURNAL OF CLINICAL ONCOLOGY

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

(2012) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance

(2012) E Jabbour et al.   LEUKEMIA

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

(2012) M Talpaz et al.   LEUKEMIA

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

(2012) F J Giles et al.   LEUKEMIA

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

(2012) R A Larson et al.   LEUKEMIA

Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia

(2012) Juan Luis Steegmann et al.   LEUKEMIA & LYMPHOMA

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate

(2012) Sung-Eun Lee et al.   Cancer Genetics

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia

(2011) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

(2011) D. Milojkovic et al.   BLOOD

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

(2011) F. E. Nicolini et al.   BLOOD

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

(2011) A. Fabarius et al.   BLOOD

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

(2011) Q. Jiang et al.   BLOOD

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

(2011) G. Marzocchi et al.   BLOOD

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

(2011) F. Efficace et al.   BLOOD

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

(2011) J. Hasford et al.   BLOOD

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

(2011) G. Gugliotta et al.   BLOOD

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

(2011) S. Chu et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

How I treat childhood CML

(2011) J. R. Andolina et al.   BLOOD

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile

(2011) W. T. Parker et al.   BLOOD

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

(2011) Gianantonio Rosti et al.   CANCER TREATMENT REVIEWS

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

(2011) Richard A. Larson et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry

(2011) Edgar Faber et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbidities

(2011) P. Valent   HAEMATOLOGICA

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

(2011) D. L. White et al.   HAEMATOLOGICA

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

(2011) N. Takahashi et al.   HAEMATOLOGICA

Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Sensitive Detection ofBCR-ABL1Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy

(2011) Wendy T. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

(2011) Elias Jabbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

(2011) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Severe Peripheral Arterial Disease During Nilotinib Therapy

(2011) P. Le Coutre et al.   JNCI-Journal of the National Cancer Institute

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

(2011) M Pfirrmann et al.   LEUKEMIA

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

(2011) F X Gruber et al.   LEUKEMIA

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

(2011) P J Shami et al.   LEUKEMIA

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

(2011) F J Giles et al.   LEUKEMIA

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

(2011) P D le Coutre et al.   LEUKEMIA

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib

(2010) M. Sobrinho-Simoes et al.   BLOOD

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

(2010) E. Jabbour et al.   BLOOD

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

(2010) J. Pavlu et al.   BLOOD

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations

(2010) E. Jabbour et al.   BLOOD

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

(2010) X. Jiang et al.   BLOOD

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

(2010) H. M. Kantarjian et al.   BLOOD

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

(2010) Jorge Cortes et al.   CANCER

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

(2010) F. Cervantes et al.   HAEMATOLOGICA

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

(2010) Deborah L. White et al.   JOURNAL OF CLINICAL ONCOLOGY

Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis

(2010) Fausto Castagnetti et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

(2010) E Jabbour et al.   LEUKEMIA

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

(2010) F J Giles et al.   LEUKEMIA

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

(2010) D Bixby et al.   LEUKEMIA

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed

(2010) Lina Eliasson et al.   LEUKEMIA RESEARCH

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

(2009) N. Testoni et al.   BLOOD

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase

(2009) C. Fava et al.   BLOOD

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

(2009) E. Jabbour et al.   BLOOD

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

(2009) A. Quintas-Cardama et al.   BLOOD

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

(2009) S. Soverini et al.   BLOOD

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

(2009) S. K. McWeeney et al.   BLOOD

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

(2009) S. Saussele et al.   BLOOD

Dysregulation of bone remodeling by imatinib mesylate

(2009) K. Vandyke et al.   BLOOD

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

(2009) Michele Baccarani et al.   BLOOD

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

(2009) L. Noens et al.   BLOOD

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

(2009) H. Kantarjian et al.   BLOOD

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

(2009) F. Palandri et al.   HAEMATOLOGICA

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

(2009) D. Milojkovic et al.   HAEMATOLOGICA

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

(2009) Jane F. Apperley et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Harmonization of molecular monitoring of CML therapy in Europe

(2009) M C Müller et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

(2008) T. P. Hughes et al.   BLOOD

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

(2008) C. S. Tam et al.   BLOOD

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

(2008) D. Marin et al.   BLOOD

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

(2008) T. Ernst et al.   HAEMATOLOGICA

Monitoring treatment of chronic myeloid leukemia

(2008) M. Baccarani et al.   HAEMATOLOGICA

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

(2008) J Cortes et al.   LEUKEMIA